Review Article
Ribavirin at the Era of Novel Direct Antiviral Agents for the Treatment of Hepatitis C Virus Infection: Relevance of Pharmacological Monitoring
Table 3
Virological response for dialysis patients or for patients with renal insufficiency (perprotocol analysis).
| Patients () | Dialysis patients () (%) | Patients with moderate or severe renal insufficiency () (%) |
| Virological response at W12 | | | EVR | 13/17 | 23/46 | RVR | 2/17 | 1/46 | cEVR | 7 | 10 | pEVR | 4 | 12 |
| Virological response at W24 | 8/13 (62) | 14/40 (35) | HCV genotype | | | 1 | 4/8 (50) | 8/31 (26) | 2 | 2/2 (100) | 3/3 (100) | 3 | 1/1 (100) | 3/5 (60) | 4 | 1/2 (50) | 0/1 (0) | Fibrosis stage | | | F0/F1/F2 | 6/8 (75) | 11/29 (38) | F3/F4 | 2/5 (40) | 6/11 (55) |
| Early treatment discontinuation | 2 | 5 | Severe anaemia | 1 | 4 | Death | 1 | 0 | Intolerance to interferon | 0 | 1 |
|
|
cEVR, complete early virological response; EVR, early virological response; pEVR, partial early virological response; RVR, rapid virological response.
|